The combination of huperzine A and imidazenil is an effective strategy to prevent diisopropyl fluorophosphate toxicity in mice.
Diisopropyl fluorophosphate (DFP) causes neurotoxicity related to an irreversible inhibition of acetylcholinesterase (AChE). Management of this intoxication includes: (i) pretreatment with reversible blockers of AChE, (ii) blockade of muscarinic receptors with atropine, and (iii) facilitation of GABA(A) receptor signal transduction by benzodiazepines. The major disadvantage associated with this treatment combination is that it must to be repeated frequently and, in some cases, protractedly. Also, the use of diazepam (DZP) and congeners includes unwanted side effects, including sedation, amnesia, cardiorespiratory depression, and anticonvulsive tolerance. To avoid these treatment complications but safely protect against DFP-induced seizures and other CNS toxicity, we adopted the strategy of administering mice with (i) small doses of huperzine A (HUP), a reversible and long-lasting (half-life approximately 5 h) inhibitor of AChE, and (ii) imidazenil (IMI), a potent positive allosteric modulator of GABA action selective for alpha(5)-containing GABA(A) receptors. Coadministration of HUP (50 microg/kg s.c., 15 min before DFP) with IMI (2 mg/kg s.c., 30 min before DFP) prevents DFP-induced convulsions and the associated neuronal damage and mortality, allowing complete recovery within 18-24 h. In HUP-pretreated mice, the ED(50) of IMI to block DFP-induced mortality is approximately 10 times lower than that of DZP and is devoid of sedation. Our data show that a combination of HUP with IMI is a prophylactic, potent, and safe therapeutic strategy to overcome DFP toxicity.
Pibiri
Fabio
F
Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois, Chicago, IL 60612, USA.
Kozikowski
Alan P
AP
Pinna
Graziano
G
Auta
James
J
Kadriu
Bashkim
B
Costa
Erminio
E
Guidotti
Alessandro
A
D000470:Alkaloids; D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology*; D003072:Cognition Disorders / Q000139:chemically induced / Q000517:prevention & control; D004359:Drug Therapy, Combination; D007093:Imidazoles / Q000494:pharmacology*; D007531:Isoflurophate / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D007928:Lethal Dose 50; D008124:Locomotion / Q000187:drug effects; D008297:Male; D051379:Mice; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control; D012717:Sesquiterpenes / Q000494:pharmacology*
D000470:Alkaloids; D007093:Imidazoles; D012717:Sesquiterpenes; C050426:huperzine A; D001569:Benzodiazepines; D007531:Isoflurophate; C082661:imidazenil
J Appl Toxicol. 1994 Sep-Oct;14(5):317-31
7822680
Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6889-93
8341715
Drug Chem Toxicol. 2001 May;24(2):165-80
11360433
Acta Neuropathol. 1983;61(2):123-9
6637396
Pharmacol Biochem Behav. 1990 Oct;37(2):267-71
2080189
Pharmacol Biochem Behav. 1993 Feb;44(2):343-7
8446666
Trends Pharmacol Sci. 1996 May;17(5):192-200
8669126
J Appl Toxicol. 2001 Dec;21 Suppl 1:S47-51
11920920
Mol Pharmacol. 1996 May;49(5):822-31
8622632
BMJ. 2004 Nov 20;329(7476):1231-3
15550429
Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
4110397
Nature. 1999 Oct 21;401(6755):796-800
10548105
J Pharmacol Exp Ther. 1995 Jun;273(3):1307-12
7791102
Psychopharmacology (Berl). 2005 Jul;180(2):191-205
15864560
Neuropharmacology. 2004 Mar;46(3):397-403
14975695
Fundam Appl Toxicol. 1994 May;22(4):588-93
8056205
Mil Med. 2001 Dec;166(12 Suppl):21-2
11778422
Br J Anaesth. 1989 Dec;63(6):736-50
2692674
Science. 2005 Jun 24;308(5730):1841
15976273
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5567-72
18391192
J Pharmacol Exp Ther. 1993 Aug;266(2):1018-28
8394902
Cochrane Database Syst Rev. 2001;(2):CD001499
11405996
Neurotoxicology. 2002 May;23(1):1-5
12164543
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2314-9
10696114
Lancet. 2002 Jan 19;359(9302):265-6
11812600
Neurotoxicology. 2001 Feb;22(1):29-37
11307848
Pharmacol Biochem Behav. 1998 Apr;59(4):1061-7
9586868
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2719-23
9122263
Biochem Biophys Res Commun. 1992 Apr 30;184(2):719-26
1575745
Neurotox Res. 2000;2(1):17-22
15545002
Pharmacol Biochem Behav. 2000 Jan 1;65(1):175-82
10638651
J Pharmacol Exp Ther. 1994 Sep;270(3):1262-9
7932179
Behav Pharmacol. 1995 Jun;6(4):323-332
11224341
J Med Chem. 1991 Dec;34(12):3399-402
1766006
Drug Chem Toxicol. 2001 May;24(2):151-64
11360432
J Pharmacol Exp Ther. 1991 Nov;259(2):633-8
1941611
Zhongguo Yao Li Xue Bao. 1995 Sep;16(5):396-8
8701751
Pharmacol Biochem Behav. 1996 Sep;55(1):99-105
8870044
J Comp Physiol Psychol. 1969 May;68(1):129-35
5793861
Life Sci. 1994;54(14):991-7
8139389
J Appl Toxicol. 1995 Jul-Aug;15(4):263-6
7594194